Evidence map›Paper›PMID 41534079›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Biocatalytic Nanoregulators Restore Joint Redox-Immune Homeostasis in Rheumatoid Arthritis.

Xingheng Wang, Jianbo Huang, Shuwei Zhang, Sujiao Cao, Fangxue Du, Liqiang Zhou, Li Qiu, Yuanjiao Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Biocatalytic Nanoregulators Restore Joint Redox-Immune Homeostasis in Rheumatoid Arthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xingheng WangDepartment of Ultrasound, National Clinical Research Center for Geriatrics, Med-X Center for Materials, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jianbo HuangDepartment of Ultrasound, National Clinical Research Center for Geriatrics, Med-X Center for Materials, West China Hospital, Sichuan University, Chengdu, 610041, China.
Shuwei ZhangDepartment of Ultrasound, National Clinical Research Center for Geriatrics, Med-X Center for Materials, West China Hospital, Sichuan University, Chengdu, 610041, China.
Sujiao CaoDepartment of Ultrasound, National Clinical Research Center for Geriatrics, Med-X Center for Materials, West China Hospital, Sichuan University, Chengdu, 610041, China.
Fangxue DuDepartment of Ultrasound, National Clinical Research Center for Geriatrics, Med-X Center for Materials, West China Hospital, Sichuan University, Chengdu, 610041, China.
Liqiang ZhouMOE Frontiers Science Center for Precision Oncology, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.ORCID https://orcid.org/0000-0002-1184-4036
Li QiuDepartment of Ultrasound, National Clinical Research Center for Geriatrics, Med-X Center for Materials, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yuanjiao TangDepartment of Ultrasound, National Clinical Research Center for Geriatrics, Med-X Center for Materials, West China Hospital, Sichuan University, Chengdu, 610041, China.

Funding

National Key R&D Program of China 2023YFC2410802National Natural Science Foundations of China 82202161National Natural Science Foundations of China 82272003National Natural Science Foundations of China 82302195National Natural Science Foundations of China 82302369Science and Technology Development Fund, Macau SAR 0032/2023/ITP1Sichuan Science and Technology Program 2023NSFSC1723Sichuan Science and Technology Program 2025YFHZ0232
6 · The paper itself

Abstract

Rheumatoid arthritis (RA), a debilitating autoimmune disorder marked by progressive synovitis and osteochondral erosion, presents critical therapeutic challenges due to the limitations of existing regimens, including non-specific biodistribution and compromised risk-benefit profiles. In this study, a novel therapeutic approach is proposed utilizing mesenchymal stem cell-derived extracellular vesicles (EVs) coating on ruthenium-loaded metal-organic frameworks (Ru@ZrMOF), which exhibit catalase mimetic activities. The EVs coating enhances the biocompatibility and targeting efficiency of the Ru@ZrMOF, while also promoting cartilage protection. Through reactive oxygen species (ROS) scavenging and oxygen production, Ru@ZrMOF/EVs significantly alleviate joint inflammation, promote cartilage protection, and inhibit pannus formation. The therapeutic mechanism involves polarization of macrophages from the M1 pro-inflammatory phenotype to the M2 anti-inflammatory phenotype, facilitating a shift in cytokine profiles from pro-inflammatory to anti-inflammatory, and downregulation of hypoxia inducible factor-1α. These findings demonstrate that Ru@ZrMOF/EVs offer a promising strategy for RA treatment by addressing both inflammation and tissue protection through targeted ROS regulation and immune modulation.

Indexed as

Anti-Inflammatory AgentsArthritis, RheumatoidBiomimetic MaterialsExtracellular VesiclesMetal-Organic FrameworksNanostructuresAnimalsDisease Models, AnimalFree Radical ScavengersHomeostasisHumansJointsMaleMesenchymal Stem CellsMiceOxidation-ReductionAnti-Inflammatory AgentsFree Radical ScavengersMetal-Organic FrameworksReactive Oxygen SpeciesRutheniumZirconiumanti‐inflammatoryextracellular vesiclesjoint protectionmacrophage polarizationrheumatoid arthritistargeted therapy

Identifiers

PMID41534079
PMCPMC12915140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.